Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study
Helsinki, Finland & Evry, France, 13 June 2023 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. ValoTx’s PeptiCRAd-1 combines the power of a tumour-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumour peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumour-specific, cytotoxic T-cells that will attack and kill cancer cells.
